Float Short %

6.95

Margin Of Safety %

Put/Call OI Ratio

1.02

EPS Next Q Diff

1.29

EPS Last/This Y

-0.52

EPS This/Next Y

1.15

Price

10.2

Target Price

10.3

Analyst Recom

Performance Q

17.26

Relative Volume

0.66

Beta

1.31

Ticker: ITOS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-25	ITOS	10.18	1.03	10.88	26374
2025-07-28	ITOS	10.12	1.05	0.00	26698
2025-07-29	ITOS	10.12	0.96	7.84	25593
2025-07-30	ITOS	10.12	0.97	0.00	25916
2025-07-31	ITOS	10.14	0.97	0.16	25987
2025-08-01	ITOS	10.1	0.92	20.14	26940
2025-08-04	ITOS	10.09	0.93	3.78	27085
2025-08-05	ITOS	10.1	0.94	10.00	27385
2025-08-06	ITOS	10.1	0.94	999.99	27418
2025-08-07	ITOS	10.12	0.96	0.00	27692
2025-08-08	ITOS	10.11	0.95	999.99	27745
2025-08-11	ITOS	10.11	0.95	999.99	27755
2025-08-12	ITOS	10.1	0.96	0.46	27807
2025-08-13	ITOS	10.13	0.97	0.00	27633
2025-08-14	ITOS	10.12	1.02	0.00	26892
2025-08-15	ITOS	10.11	1.02	0.01	26890
2025-08-18	ITOS	10.11	1.03	0.24	24240
2025-08-19	ITOS	10.13	1.02	2.26	24345
2025-08-20	ITOS	10.2	1.02	4.00	24513
2025-08-21	ITOS	10.2	1.02	0.73	24528
2025-08-22	ITOS	10.2	1.02	0.38	24696
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-25	ITOS	10.17	-342.4	-	-3.34
2025-07-28	ITOS	10.12	-358.3	-	-3.34
2025-07-29	ITOS	10.11	-358.3	-	-3.34
2025-07-30	ITOS	10.12	-358.3	-	-3.34
2025-07-31	ITOS	10.14	-358.3	-	-3.34
2025-08-01	ITOS	10.09	-358.3	-	-3.34
2025-08-04	ITOS	10.10	-358.3	-	-3.34
2025-08-05	ITOS	10.11	-358.3	-	-3.34
2025-08-06	ITOS	10.11	-358.3	-	-3.34
2025-08-07	ITOS	10.13	-358.3	-	-3.34
2025-08-08	ITOS	10.11	-358.3	-	-3.34
2025-08-11	ITOS	10.12	2.9	-	-3.34
2025-08-12	ITOS	10.11	2.9	-	-3.34
2025-08-13	ITOS	10.12	2.9	-	-3.34
2025-08-14	ITOS	10.12	2.9	-	-3.34
2025-08-15	ITOS	10.11	2.9	-	-3.84
2025-08-18	ITOS	10.10	2.9	-	-3.84
2025-08-19	ITOS	10.13	2.9	-	-3.84
2025-08-20	ITOS	10.21	2.9	-	-3.84
2025-08-21	ITOS	10.20	2.9	-	-3.84
2025-08-22	ITOS	10.20	2.9	-	-3.84
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-25	ITOS	0	32.06	8.56
2025-07-28	ITOS	0	23.58	8.56
2025-07-29	ITOS	0	23.58	8.56
2025-07-30	ITOS	0	23.58	8.56
2025-07-31	ITOS	0	23.58	8.56
2025-08-01	ITOS	0	23.58	8.56
2025-08-04	ITOS	0	25.83	8.56
2025-08-05	ITOS	0	25.83	8.56
2025-08-06	ITOS	0	25.83	8.56
2025-08-07	ITOS	0	25.83	8.56
2025-08-08	ITOS	0	25.83	8.56
2025-08-11	ITOS	480.50	26.18	0
2025-08-12	ITOS	480.50	26.18	7.16
2025-08-13	ITOS	480.50	26.18	7.16
2025-08-14	ITOS	480.55	26.18	7.16
2025-08-15	ITOS	480.51	26.18	7.16
2025-08-18	ITOS	480.50	20.62	6.95
2025-08-19	ITOS	153.76	20.62	6.95
2025-08-20	ITOS	153.76	20.62	6.95
2025-08-21	ITOS	153.76	20.62	6.95
2025-08-22	ITOS	153.76	20.62	6.95
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.51

Avg. EPS Est. Current Quarter

-1.02

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

153.76

Institutional Transactions

20.62

Beta

1.31

Average Sales Estimate Current Quarter

-6

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.6

Max Drawdown 5-Year %

-89.5

Target Price

10.3

P/E

Forward P/E

PEG

P/S

P/B

0.91

P/Free Cash Flow

EPS

-4.85

Average EPS Est. Cur. Y

-3.84

EPS Next Y. (Est.)

-2.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.66

Return on Equity vs Sector %

-65.7

Return on Equity vs Industry %

-52.8

EPS 1 7Days Diff

-0.5

EPS 1 30Days Diff

-0.5

EBIT Estimation

iTeos Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 173

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

stock quote shares ITOS – ITeos Therapeutics Inc Stock Price stock today

news today ITOS – ITeos Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ITOS – ITeos Therapeutics Inc yahoo finance google finance

stock history ITOS – ITeos Therapeutics Inc invest stock market

stock prices ITOS premarket after hours

ticker ITOS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ITOS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y